Treatment-resistant Churg-Strauss syndrome: Progression after five years using rituximab;Síndrome de Churg Strauss refractario al tratamiento, evolución a los cinco años del empleo de rituximab

Nefrologia

Volumn 33, Issue 5, 2013, Pages 737-739

  Martínez Villaescusa, María ^a   López Montes, Aurora ^a   López Rubio, Esperanza ^a   de la Vara Iniesta, Lourdes ^a   Méndez Molina, Marina ^a   Donate Ortiz, Dionisio ^a   Nam Cha, Hyun ^a   Gómez Roldán, Carmen ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB;

AGED; BIOPSY; CASE REPORT; CHURG STRAUSS SYNDROME; DISEASE COURSE; DRUG RESISTANCE; GLOMERULONEPHRITIS; HUMAN; IMMUNOLOGY; KIDNEY; LETTER; MALE; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PLASMAPHERESIS; REMISSION; RENAL REPLACEMENT THERAPY;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOPSY; CHURG-STRAUSS SYNDROME; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DRUG RESISTANCE; GLOMERULONEPHRITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; MALE; METHYLPREDNISOLONE; PLASMAPHERESIS; PREDNISONE; REMISSION INDUCTION; RENAL DIALYSIS;

EID: 84885363545     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2013.May.12101     Document Type: Letter

References (13)

1. Noth I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet 2003;361:587-94.
2. Clutterbuck EJ, Evans DJ, Pusey CD. Renal involment in Churg-Strauss syndrome. Nephrol Dial Transplant 1990;5:161-7.
3. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010;363:221-32.
4. Jennnete JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Goss WL, et al. Nomenclatura of systemic systemic vasculitides. Proposal of an internacional consensos conference. Arthritis Rheum 1994;37:187-92.
5. Merino JL, Galeano C, Espejo B, Rivera M, Fernandez-Lucas M, Caldés S, et al. A retrospective study on outcome of microscopio polyangiitis in chronic renal replacement therapy. Nephrol Dial Transplant 2011;26:1360-6.
6. Gayraud M, Guillevin L, le Toumelin P, Cohen P, Lhote F, Casassus P, et al.; French Vasculitis Study Group. Long-term follow-up of polyarteritis nodosa, microscopic poliangiitis and Churg Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001;44(3):666-75.
7. Mitchison NA. T-cell-B-cell cooperation. Nat Rev Immunol 2004;4:308-12.
8. Stasi R, Stipa E, Del Poeta G, Amadori S, Newland AC, Provan D. Long-term observation of patients with antineutrophil cytoplasmic antibodyassociated vasculitis treated with rituximab. Rheumatology (Oxford) 2006;45:1432-6.
9. Rocatello D, Baldovino S, Alpa M, Rossi D, Napoli F, Naretto C, et al. Effects of anti-CD20 monoclonal antibody as a rescue treatment for ANCA-associated idiopathic systemic vasculitis with or without overt renal involvement. Clin Exp Rheumatol 2008;26(3 Suppl 49):S67-71.
10. Keogh KA, Wylliam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody associated vasculitis. Arthritis Rheum 2005;52:262-8.
11. Gottenberg JE, Gullevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64:913-20.
12. Saech J, Owczarczyk K, Rösgen S, Petereit H, Hallek M, Rubbert-Roth A. Sucessful use of rituximab in a patient with Churg-Strauss syndrome and refractory central nervous system involment. Ann Rheum Dis 2010;69(6):1254-5.
13. Cartin-Ceba R, Keogh KA, Specks U, Sethi S, Fervenza FC. Rituximab for the treatment of Churg-Strauss syndrome with renal involment. Nephrol Dial Transplant 2011;26:2865-71.